A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rats

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 2, 2012, Pages 139-144

  Sunagawa, Yoichi ^a,b,c   Wada, Hiromichi ^b   Suzuki, Hidetoshi ^c   Sasaki, Hiroki ^d   Imaizumi, Atsushi ^d   Fukuda, Hiroyuki ^d   Hashimoto, Tadashi ^d   Katanasaka, Yasufumi ^c   Shimatsu, Akira ^b   Kimura, Takeshi ^a   Kakeya, Hideaki ^a   Fujita, Masatoshi ^a   Hasegawa, Koji ^b   Morimoto, Tatsuya ^c  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

^d Theravalues Corporation   (Japan)

Author keywords

Curcumin; Drug delivery system; Heart failure

Indexed keywords

CURCUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HEART INFARCTION; HEART LEFT VENTRICLE; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANIMALS; CARDIOTONIC AGENTS; CURCUMIN; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GUM ARABIC; HEART FAILURE; HEMODYNAMICS; INTESTINAL ABSORPTION; MALE; MYOCARDIAL INFARCTION; P300-CBP TRANSCRIPTION FACTORS; PLANT GUMS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84863408918     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.139     Document Type: Article

References (22)

1. Hasegawa K, Lee SJ, Jobe SM, Markham BE, Kitsis RN. cis-Acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation, 96, 3943-3953 (1997).
2. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, Sasayama S. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J. Biol. Chem., 275, 13721-13726 (2000).
3. Yanazume T, Hasegawa K, Morimoto T, Kawamura T, Wada H, Matsumori A, Kawase Y, Hirai M, Kita T. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol., 23, 3593-3606 (2003).
4. Miyamoto S, Kawamura T, Morimoto T, Ono K, Wada H, Kawase Y, Matsumori A, Nishio R, Kita T, Hasegawa K. Histone acetyl-transferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation, 113, 679-690 (2006).
5. Sunagawa Y, Morimoto T, Takaya T, Kaichi S, Wada H, Kawamura T, Fujita M, Shimatsu A, Kita T, Hasegawa K. Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. J. Biol. Chem., 285, 9556-9568 (2010).
6. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K. The dietary compound curcumin inhibits p300 histone acetyl-transferase activity and prevents heart failure in rats. J. Clin. Invest., 118, 868-878 (2008).
7. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ. J., 75, 2151-2159 (2011).
8. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol., 4, 1502-1506 (2006).
9. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull., 34, 660-665 (2011).
10. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. (Weinheim), 343, 489-499 (2010).
11. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem., 102, 1095-1104 (2007).
12. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr. Pharm. Des., 15, 2087-2094 (2009).
13. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 14, 4491-4499 (2008).
14. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett., 255, 170-181 (2007).
15. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm., 4, 807-818 (2007).
16. Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int. J. Pharm., 244, 127-135 (2002).
17. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 853, 183-189 (2007).
18. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 86, 215-223 (2009).
19. Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int. J. Pharm., 416, 331-338 (2011).
20. Song Z, Feng R, Sun M, Guo C, Gao Y, Li L, Zhai G. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J. Colloid Interface Sci., 354, 116-123 (2011).
21. Pandelidou M, Dimas K, Georgopoulos A, Hatziantoniou S, Demetzos C. Preparation and characterization of lyophilised egg PC liposomes incorporating curcumin and evaluation of its activity against colorectal cancer cell lines. J. Nanosci. Nanotechnol., 11, 1259-1266 (2011).
22. Gao Y, Li Z, Sun M, Li H, Guo C, Cui J, Li A, Cao F, Xi Y, Lou H, Zhai G. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev. Ind. Pharm., 36, 1225-1234 (2010).